CSBIO(SZ:300255) Xin Lang Zheng Quan·2025-09-03 01:40Group 1 - The core viewpoint of the news highlights the recent performance and financial metrics of Changshan Pharmaceutical, including stock price movements and trading volumes [1][2] - On September 2, Changshan Pharmaceutical's stock fell by 4.27%, with a trading volume of 1.565 billion yuan. The net financing purchase on that day was 15.3582 million yuan, with a total financing and securities balance of 1.985 billion yuan [1] - The financing balance of Changshan Pharmaceutical accounts for 4.44% of its circulating market value, indicating a high level compared to the past year [1] Group 2 - As of August 29, the number of shareholders of Changshan Pharmaceutical decreased to 49,500, while the average circulating shares per person increased by 6.61% to 18,525 shares [2] - For the first half of 2025, Changshan Pharmaceutical reported an operating income of 492 million yuan, a year-on-year decrease of 13.42%, and a net profit attributable to shareholders of -29.089 million yuan, which represents a year-on-year increase of 37.98% [2] - The company has distributed a total of 181 million yuan in dividends since its A-share listing, with 4.5953 million yuan distributed over the past three years [2]